The earnings call highlighted strong financial performance and strategic growth initiatives, particularly within Evernorth. However, challenges such as elevated medical costs and pressures in specific business segments like the individual exchanges and stop-loss margins were noted.

Company Guidance -

Q3 2025

During the Cigna Group's second quarter 2025 results review, the company provided comprehensive guidance reaffirming their full year 2025 adjusted earnings per share outlook of at least $29.60. For the second quarter, Cigna reported total revenue of $67.2 billion and increased adjusted earnings per share to $7.20. The company highlighted sustained momentum across its key platforms, Evernorth and Cigna Healthcare, with Evernorth contributing over 60% of enterprise earnings. In Evernorth, Specialty and Care Services revenue grew 13% to $25.9 billion, and Pharmacy Benefit Services continued to exhibit strong client retention. Cigna Healthcare reported a medical care ratio of 83.2%, emphasizing disciplined execution amid elevated medical costs. For 2025, Cigna anticipates continued elevated cost trends, projecting a full year medical care ratio between 83.2% and 84.2%, while maintaining robust capital management with strong cash flow expectations in the second half.

Strong Financial Performance

The Cigna Group delivered $67.2 billion in total revenue and grew adjusted earnings per share to $7.20, continuing their track record of sustained attractive results.

Evernorth's Growth

Evernorth achieved strong earnings slightly ahead of expectations with momentum in Specialty and Care Services and good execution in Pharmacy Benefit Services. Specialty prescription volume increased, leading to 12% growth in normalized earnings.

Strategic Partnership with Prime Therapeutics

Evernorth finalized a multiyear contract extension with Prime Therapeutics, highlighting strong client retention and demand across diverse buyer groups.

Innovative GLP-1 Benefit Program

Evernorth launched a new benefit option that limits the patient's out-of-pocket cost for GLP-1 weight loss prescriptions to no more than $200 per month, enhancing affordability and choice.

Cigna (CI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	7.65 / -	7.51	―	―	―
Jul 31, 2025	2025 (Q2)	7.16 / 7.20	6.72	7.14% (+0.48)	―
May 02, 2025	2025 (Q1)	6.35 / 6.74	6.47	4.17% (+0.27)	―
Jan 30, 2025	2024 (Q4)	7.83 / 6.64	6.79	-2.21% (-0.15)
Oct 31, 2024	2024 (Q3)	7.23 / 7.51	6.77	10.93% (+0.74)
Aug 01, 2024	2024 (Q2)	6.43 / 6.72	6.13	9.62% (+0.59)
May 02, 2024	2024 (Q1)	6.22 / 6.47	5.41	19.59% (+1.06)
Feb 02, 2024	2023 (Q4)	6.54 / 6.79	4.96	36.90% (+1.83)
Nov 02, 2023	2023 (Q3)	6.68 / 6.77	6.04	12.09% (+0.73)
Aug 03, 2023	2023 (Q2)	6.03 / 6.13	6.22	-1.45% (-0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$297.86	$267.38	-10.23%
May 02, 2025	$333.57	$333.14	-0.13%
Jan 30, 2025	$300.38	$280.25	-6.70%
Oct 31, 2024	$308.57	$310.46	+0.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.